Posted by zeugma on March 23, 2006, at 19:15:49
In reply to Gee, its a real shame about Gepirone, posted by linkadge on March 23, 2006, at 18:21:37
i couldn't agree more about the failure of gepirone to be deemed approvable.
of all the drugs in its class buspirone has the lowest parent-to-metabolite ratio, and the highest D2 affinity, thus it is the least desirable member of its class.
Even an ER formulation of buspirone would be useful, but it won't happen. And gepirone is not owned by a company with the clout of, say, Wyeth, whose Effexor metabolite will soon reach the market, and no doubt will prove a valuable advance for those who already respond to Effexor, since the two chemical entities are virtually identical.
-z
poster:zeugma
thread:623699
URL: http://www.dr-bob.org/babble/20060322/msgs/623852.html